SKYTROFA

Drug Ascendis Pharma, Inc.
Total Payments
$5.8M
Transactions
4,364
Doctors
818
Companies
2

Payment Trends by Year

Year Amount Transactions Doctors
2023 $3.3M 1,971 620
2022 $2.4M 2,393 450

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $4.9M 809 84.4%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $473,584 218 8.2%
Consulting Fee $210,519 67 3.6%
Travel and Lodging $124,994 555 2.2%
Food and Beverage $92,932 2,691 1.6%
Education $273.76 24 0.0%

Payments by Type

Research
$4.9M
809 transactions
General
$902,303
3,555 transactions

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
foresiGHt Ascendis Pharma Inc $1.3M 0
enliGHten Ascendis Pharma, Inc. $1.1M 0
foresiGHt Ascendis Pharma, Inc. $943,826 0
New InsiGHts Ascendis Pharma Inc $590,868 0
foresiGHt extension Ascendis Pharma Inc $478,392 0
enliGHten Ascendis Pharma Inc $469,066 0

Top Doctors Receiving Payments for SKYTROFA — Page 33

Doctor Specialty Location Total Records
, APRN Registered Nurse Cincinnati, OH $13.72 1
, M.D Pediatric Endocrinology Novi, MI $13.65 1
, MD Internal Medicine Fairfield, OH $13.43 1
, CRNP Family Mobile, AL $13.35 1
, PA Physician Assistant Salt Lake City, UT $13.28 1
Evelyn Artz Endocrinology, Diabetes & Metabolism Johnson City, TN $13.20 1
, FNP Family Johnson City, TN $13.20 1
, DNP, NP Nurse Practitioner Baltimore, MD $13.19 1
, D.O Family Medicine Saint Louis, MO $13.12 1
, M.D Internal Medicine Saint Louis, MO $13.12 1
, MBBS Pediatrics Boston, MA $13.08 1
, M.D Pediatrics Boston, MA $13.08 1
, DO Emergency Medicine Hackensack, NJ $13.04 1
, M.D Surgery Ann Arbor, MI $13.04 1
, CPNP Pediatrics Lansing, MI $13.04 1
, M.D Pediatrics Dallas, TX $7.58 1
, M.D Pediatric Endocrinology Dallas, TX $7.58 1
, MD Pediatric Endocrinology Wichita, KS $7.58 1
Douglas Sobel Pediatric Endocrinology Boston, MA $7.58 1

About SKYTROFA

SKYTROFA is a drug associated with $5.8M in payments to 818 healthcare providers, recorded across 4,364 transactions in the CMS Open Payments database. The primary manufacturer is Ascendis Pharma, Inc..

Payment data is available from 2022 to 2023. In 2023, $3.3M was paid across 1,971 transactions to 620 doctors.

The most common payment nature for SKYTROFA is "Unspecified" ($4.9M, 84.4% of total).

SKYTROFA is associated with 6 research studies, including "foresiGHt" ($1.3M).